Sun BioPharma, Inc. Doses First Patients in Second Clinical Study of SBP-101 for Pancreatic Ductal Adenocarcinoma (Globe Newswire)
UF startup Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd, a clinical stage biopharmaceutical company developing disruptive therapeutics for the... Read More